
Releases
AbbVie Reports Nine-Year Outcomes for Venetoclax in CLL Treatment
Patients with previously untreated chronic lymphocytic leukemia saw sustained benefits from a fixed-duration regimen of venetoclax and obinutuzumab, according to nine-year results from the Phase 3 CLL14 trial presented at the European Hematology Association 2026 Congress in Stockholm.























